Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Regeneron Pharmaceuticals's Accounts Payable for the quarter that ended in Jun. 2026 was R$5,940 Mil.
Regeneron Pharmaceuticals's quarterly Accounts Payable
increased
from Dec. 2025 (R$5,123 Mil) to Mar. 2026 (R$5,371 Mil) and
increased
from Mar. 2026 (R$5,371 Mil) to Jun. 2026 (R$5,940 Mil).
Regeneron Pharmaceuticals's annual Accounts Payable
increased
from Dec. 2023 (R$2,972 Mil) to Dec. 2024 (R$4,817 Mil) and
increased
from Dec. 2024 (R$4,817 Mil) to Dec. 2025 (R$5,123 Mil).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.
Regeneron Pharmaceuticals (BSP:REGN34) has a Accounts Payable of R$5,940 Mil as of Jun. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Regeneron Pharmaceuticals and its competitors.
Is Regeneron Pharmaceuticals' Accounts Payable too high?
Regeneron Pharmaceuticals' current Accounts Payable is R$5,940 Mil. Overall, Regeneron Pharmaceuticals has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Regeneron Pharmaceuticals' Accounts Payable compare to RVMD and ALNY?
Regeneron Pharmaceuticals' Accounts Payable of R$5,940 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Regeneron Pharmaceuticals and its competitors. Regeneron Pharmaceuticals's current Accounts Payable is R$5,940 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regeneron Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Regeneron Pharmaceuticals (BSP:REGN34) is currently considered Fairly Valued. The stock's GF Value™ is R$75.03, compared to a current price of R$69.16 — trading 7.8% below its estimated fair value. The current Accounts Payable is R$5,940 Mil. Regeneron Pharmaceuticals' overall GF Score™ is 89/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Regeneron Pharmaceuticals (BSP:REGN34), the current Accounts Payable is R$5,940 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Regeneron Pharmaceuticals (BSP:REGN34) Overvalued in 2026?
Based on GuruFocus' analysis, Regeneron Pharmaceuticals stock appears to be undervalued.
The current stock price of R$69.16 is trading 7.8% below its estimated GF Value™ of R$75.03.
GuruFocus considers Regeneron Pharmaceuticals to be Fairly Valued.
Key valuation signals for BSP:REGN34:
Accounts Payable: R$5,940 Mil
GF Value™: R$75.03 vs. price of R$69.16 (7.8% below fair value)
No single metric tells the full story. See the BSP:REGN34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
89GF Score
Get the complete analysis for BSP:REGN34
Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:REGN34 has been successfully added to your 
